Apremilast versus Methotrexate In Moderate To SeverePsoriasis : A Comparative Study

DR H ANCHTIHA0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Diagnosis of moderate to severe plaque psoriasis defined by
•BSA > 10 or PASI > 10 or DLQI >10
•2. Patients who are candidates for systemic therapy for psoriasis
•3. Inadequate response to a previous systemic treatment
•4. In good health as judged based on medical history, physical examination, serum chemistry labs, haematology values, and urinalysis.
•5. Subjects are competent to sign and give informed consent
•6. Subjects who willing to adhere to the Protocol and visit schedule.

•1.Patients with non-plaque forms of psoriasis (erythrodermic, guttate, pustular)
•2.Pregnant or lactating women
•3.Patients who had received any systemic treatment for psoriasis within 4 weeks of the baseline visit and topical treatment within the past 2 weeks of the baseline visit .
•4.Phototherapy ultraviolet A with psoralen [PUVA] within 4 weeks of the baseline visit and/or ultraviolet B (UVB) within 2 weeks of the baseline visit
•5.History of serious hypersensitivity to phosphodiesterase type 4 (PDE-4) inhibitors
•6.Subjects with history of suicidal thought or other clinically significant psychiatric diseases
•7.History of k/c/o congenital or acquired immunodeficiencies -HIV,Malignancy,Hepatitis B or C and other severe infection
•8.Subject history of active tuberculosis infection or incompletely treated active or latent tuberculosis infection
•9.Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study

发起方

DR H ANCHTIHA